甲状腺癌相关基因及其在临床诊断中应用的研究进展

doi:10.13481/j.1671-587x.20180436

[1] O'Grady TJ,Gates MA,Boscoe FP. Thyroid cancer incidence attributable to overdiagnosis in the United States 1981-2011[J].Int J Cancer,2015,137(11):2664-2673.
[2] 张波,徐景竹,吴琼.2015年美国甲状腺学会《成人甲状腺结节与分化型甲状腺癌诊治指南》解读:超声部分[J].中国癌症杂志,2016,26(1):19-24.
[3] Liu M,Ruan M,Chen L.Update on the molecular diagnosis and targeted therapy of thyroid cancer[J].Med Oncol,2014,31(6):973.
[4] Nikiforov YE.Thyroid carcinoma:molecular pathways and therapeutic targets[J].Modern Pathol,2008,21(Suppl 2):S37-S43.
[5] Nucera C,Porrello A,Antonello ZA,et al.B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression[J].Proc Natl Acad Sci USA,2010,107(23):10649-10654.
[6] Kim BA,Jee HG,Yi JW,et al.Expression profiling of a human thyroid cell Line Stably Expressing the BRAFV600E Mutation[J].Cancer Genomics Proteomics,2017,14(1):53-67.
[7] Jung CK,Im SY,Kang YJ,et al.Mutational patterns and novel mutations of the BRAF gene in a large cohort of Korean patients with papillary thyroid carcinoma[J].Thyroid,2012,22(8):791-797.
[8] Xing M.BRAF mutation in thyroid cancer[J].EndocrRelat Cancer,2005,12(2):245-262.
[9] 石臣磊,秦华东,丁超,等.鼠类肉瘤滤过性毒菌致癌同源体B1 V600 E基因突变与甲状腺乳头状癌中央区淋巴结转移的关系[J].中华肿瘤杂志,2015,37(2):123-127.
[10] 王波,赵文新.ret/PTC3基因重排在甲状腺癌中的作用机制及其研究进展[J].中华实验外科杂志,2013,30(10):2241-2242.
[11] Penna GC,Vaisman F,Vaisman M,et al.Molecular markers involved in tumorigenesis of thyroid carcinoma:focus on aggressive histotypes[J].Cytogenet Genome Res,2016,150(3/4):194-207.
[12] Su X,Li Z,He C,et al.Radiation exposure,young age,and female gender are associated with high prevalence of RET/PTC1 and RET/PTC3 in papillary thyroid cancer:a meta-analysis[J].Oncotarget,2016,7(13):16716-16730.
[13] Figlioli G,Landi S,Romei C,et al.Medullary thyroid carcinoma (MTC) and RET proto-oncogene:mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form[J].Mutat Res,2013,752(1):36-44.
[14] Romei C,Cosci B,Renzini G,et al.RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC)[J].Clin Endocrinol(Oxf),2011,74(2):241-247.
[15] Ciriello G,Cerami E,Sander C,et al.Mutual exclusivity analysis identifies oncogenic network modules[J].Genome Res,2012,22(2):398-406.
[16] Nikiforov YE,Nikiforova MN.Molecular genetics and diagnosis of thyroid cancer[J].Nat Rev Endocrinol,2011,7(10):569-580.
[17] Cifuentes-Rojas C,Shippen DE.Telomerase regulation[J].Mutat Res,2012,730(1/2):20-27.
[18] Horn S,Figl A,Rachakonda PS,et al.TERT promoter mutations in familial and sporadic melanoma[J].Science,2013,339(6122):959-961.
[19] Landa I,Ibrahimpasic T,Boucai L,et al.Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers[J].J Clin Invest,2016,126(3):1052-1066.
[20] Xing M,Liu R,Liu X,et al.BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence[J].J Clin Oncol,2014,32(25):2718-2726.
[21] Bullock M,Ren Y,O'Neill C,et al.TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas[J].Clin Endocrinol(Oxf),2016,85(2):283-290.
[22] Pavelic K,Dedivitis RA,Kapitanovic S,et al.Molecular genetic alterations of FHIT and p53 genes in benign and malignant thyroid gland lesions[J].Mutat Res,2006,599(1/2):45-57.
[23] Corapcioglu D,Sak SD,Delibasi T,et al.Papillary microcarcinomas of the thyroid gland and immunohistochemical analysis of expression of p53 protein in papillary microcarcinomas[J].J Transl Med,2006,4:28.
[24] Hasbek Z,Turgut B,Erselcan T.p53 antibody:is it an indicator of dedifferentiated thyroid cancer?[J]. Ann Nucl Med,2014,28(1):42-46.
[25] Balta AZ,Filiz AI,Kurt Y,et al.Prognostic value of oncoprotein expressions in thyroid papillary carcinoma[J].Med Oncol,2012,29(2):734-741.
[26] Tavares C,Melo M,Cameselle-Teijeiro JM,et al.Endocring tumours:Genetic predictors of thyroid cancer outcome[J].Eur J Endocrinol,2016,174(4):R117-126.
[27] Omur O,Baran Y.An update on molecular biology of thyroid cancers[J].Crit Rev Oncol Hematol,2014,90(3):233-252.
[28] Kalhori V,Tornquist K.MMP2 and MMP9 participate in S1P-induced invasion of follicular ML-1 thyroid cancer cells[J].Mol Cell Endocrinol,2015,404:113-122.
[29] 华特波,孟宪瑛,王广义,等.甲状腺组织中COX-2、MMP-9、VEGF和RET的检测及其在甲状腺乳头状癌早期诊断中的意义[J].吉林大学学报:医学版,2011,37(4):712-717.
[30] Gilbert-Sirieix M,Makoukji J,Kimura S,et al.Wnt/beta-catenin signaling pathway is a direct enhancer of thyroid transcription factor-1 in human papillary thyroid carcinoma cells[J].PLoS One,2011,6(7):e22280.
[31] Pacifico F,Leonardi A.Role of NF-kappaB in thyroid cancer[J].Mol Cell Endocrinol,2010,321(1):29-35.
[32] Cancer Genome Atlas Research.Integrated genomic characterization of papillary thyroid carcinoma[J].Cell,2014,159(3):676-690.
[33] Malapelle U,Bellevicine C,Salatiello M,et al.Sanger sequencing in routine KRAS testing:a review of 1720 cases from a pathologist's perspective[J].J Clin Pathol,2012,65(10):940-944.
[34] Schiavo S,Yang WC,Chin NH,et al.Comparison of fluorometric detection methods for quantitative polymerase chain reaction (PCR)[J].J Immunoassay Immunochem,2005,26(1):1-12.
[35] Okayama N,Fujimura K,Nakamura J,et al.Evaluation of a new efficient procedure for single-nucleotide polymorphism genotyping:tetra-primer amplification refractory mutation system-polymerase chain reaction[J].Clin Chem Lab Med,2004,42(1):13-16.
[36] Oler G,Ebina KN,Michaluart PJr,et al.Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis[J].Clin Endocrinol(Oxf),2005,62(4):509-511.
[37] Zatelli MC,Trasforini G,Leoni S,et al.BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies[J].Eur J Endocrinol,2009,161(3):467-473.
[38] Xing M,Alzahrani AS,Carson KA,et al.Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer[J].JAMA,2013,309(14):1493-1501.
[39] Hsiao SJ,Nikiforov YE.Molecular approaches to thyroid cancer diagnosis[J].Endocrine Relat Cancer,2014,21(5):T301-313.
[40] Fenton CL,Lukes Y,Nicholson D,et al.The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults[J].J Clin Endocrinol Metab,2000,85(3):1170-1175.
[41] Nikiforov YE.RET/PTC rearrangement in thyroid tumors[J].Endocr Pathol,2002,13(1):3-16.
[42] Agarwal S,Agarwal A,Chand G,et al.MEN 2A family——prophylactic thyroidectomy for asymptomatic siblings with positive 634 codon mutation[J].J Assoc Physicians India,2012,60:127-129.
[43] Gupta N,Dasyam AK,Carty SE,et al.RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular-pattern cancers[J].J Clin Endocrinol Metab,2013,98(5):E914-22.
[44] An JH,Song KH,Kim SK,et al.RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma[J].Clin Endocrinol,2015,82(5):760-766.
[45] Nikiforov YE.Molecular analysis of thyroid tumors[J].Mod Pathol,2011,24(Suppl 2):S34-S43.
[46] Jang EK,Song DE,Sim SY,et al.NRAS codon 61 mutation is associated with distant metastasis in patients with follicular thyroid carcinoma[J].Thyroid,2014,24(8):1275-1281.
[47] Alzahrani AS,Alsaadi R,Murugan AK,et al.TERT promoter mutations in thyroid cancer[J].Horm Cancer,2016,7(3):165-177.
[48] Albarel F,Conte-Devolx B,Oliver C.From nodule to differentiated thyroid carcinoma:contributions of molecular analysis in 2012[J].Ann Endocrinol(Paris),2012,73(3):155-164.

Research progress in thyroid cancer related genes and their applications in clinical diagnosis

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Comments

Recommended 10

[1]	Yixuan XU,Hui WANG. Comparison of clinical efficacy between microwave ablation and surgical treatment for Hashimoto’s thyroiditis complicated with T1aN0M0 papillary thyroid carcinoma [J]. Journal of Jilin University(Medicine Edition), 2025, 51(6): 1646-1654.
[2]	Qian AO,Jingting LI,Nan LIANG,Hui SUN. Recurrent follicular variant of papillary thyroid carcinoma with DICER1 mutation in adolescent：A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2025, 51(6): 1702-1708.
[3]	Pengqing WU,Lingpeng ZENG,Zhaoxia LUO,Yangyang LEI,Ruiqin GOU,Qing ZHANG. Thymus physiological uptake in patient with differentiated thyroid carcinoma after postoperative iodine-131 treatment: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2025, 51(5): 1358-1362.
[4]	Lingyu WANG,Weizhang SHEN,Lei TAN,Jinliang LI. Diagnosis of immune thrombotic thrombocytopenic purpura: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2024, 50(6): 1734-1740.
[5]	Shimeng LI,Xin QI,Sitong LIN,Xiangwen SAN,Ling JIN,Sitong ZHANG. Reactive plasmacytosis caused by methimazole in patients with Graves’ disease： One case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2024, 50(5): 1414-1419.
[6]	Yuxiao SHI,Meilan LIU,Meilin ZHU,Feng WEI. Effects of 5-Aza-CdR on autophagy and apoptosis of papillary thyroid cancer cells in subcutaneous xenograft tumor tissue of nude mice and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2024, 50(5): 1330-1338.
[7]	Peng QI,Xianying MENG,Meihua PIAO,Qiang ZHANG. Network Meta-analysis on risk factors of recurrence of papillary thyroid microcarcinoma [J]. Journal of Jilin University(Medicine Edition), 2023, 49(6): 1504-1512.
[8]	. Research progress in changes of hormone levels of patients with differentiated thyroid carcinoma during pregnancy and their effects on occurrence and development of disease [J]. Journal of Jilin University(Medicine Edition), 2023, 49(3): 811-815.
[9]	Zhiyuan XIAO,Bing SONG,Xinyu MA,Lianhui JIN,Tong ZHENG,Fang CHAI. Bioinformatics analysis on expression of apoptosis related gene CD44 in thyroid carcinoma tissue and its relationship with tumor invasion and immune cell infiltration [J]. Journal of Jilin University(Medicine Edition), 2023, 49(2): 473-481.
[10]	Wanyi GU,Cheng ZHI,Chunxia LIU. Intrathyroid thymic carcinoma: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2022, 48(6): 1580-1585.
[11]	. Research progress in preoperative evaluation and prognostic related factors of low-risk papillary thyroid microcarcinoma [J]. Journal of Jilin University(Medicine Edition), 2022, 48(6): 1650-1656.
[12]	Wei JI,Jian DONG,Hong CHANG,Xuemei DU,Hong PENG,Hong XIE,Aimin ZHAO,Wei YAN,Juan BAI,Zhenxing PENG,Jinshu YIN. Influence of chinicopathological characteristics and BRAF V600E gene mutation in cervical lymph node metastasis in patients with papillary thyroid cancer [J]. Journal of Jilin University(Medicine Edition), 2022, 48(4): 995-1002.
[13]	Yaoyu FENG, Chenglei ZHANG, Lijuan HOU, Yifu WANG, Xiuling WU, Yunhai MA. Effect of miR-222-3p knockdown targeting PTEN on ¹³¹I radiotherapy resistance of thyroid cancer and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2021, 47(3): 677-686.
[14]	. [J]. Journal of Jilin University(Medicine Edition), 2021, 47(3): 802-810.
[15]	Chunying ZHANG,Guangwei YIN,Mingda YOU,Hong CHEN,Yaojie HU,Yanbing LI,Chunyou CHEN. Inhibitory effects of siRNA targeting silencing TAK1 gene on proliferation and migration of thyroid cancer cells and p38 MAPK signaling pathway [J]. Journal of Jilin University(Medicine Edition), 2021, 47(1): 110-117.